New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:09 EDTVRNT, MDR, CBST, AMRN, DRTX, ARTX, MDCOOn The Fly: After Hours Movers
HIGHER: Durata Therapeutics (DRTX), up 5.4% after an FDA Committee voted in favor of its Dalvance injection for the treatment of adult patients with acute bacterial skin and skin structure infections caused by certain bacteria... Amarin (AMRN), up 8.8% after announcing a co-promotion agreement with Kowa Pharmaceuticals America for its Vascepa capsules in the U.S... Verint Systems (VRNT), up 10% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: The Medicines Company (MDCO), down 14.3% after Durata and Cubist Pharmaceuticals (CBST) each received positive votes from FDA panels for bacteria treatments that could compete with its Oritavancin. Cubist (CBST), which confirmed the FDA panel vote intraday, saw shares gain $3.05, or 4.35%, to close at $73.15 for the session... Arotech (ARTX), down 12.5% after reporting fiscal year earnings and revenue that disappointed... McDermott (MDR), down 2.8% after filing to sell 10M tangible equity units and, in a separate release, saying that its first quarter results may differ "substantially" from the company's current expectation.
News For DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
08:04 EDTARTXArotech recommences share buyback program
Subscribe for More Information
November 20, 2014
10:02 EDTCBSTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Zoetis (ZTS) downgraded to Market Perform from Outperform at William Blair... Target (TGT) downgraded to Hold from Buy at Evercore ISI... Alexandria Real Estate (ARE) downgraded to Neutral from Outperform at RW Baird... Allscripts (MDRX) downgraded to Sector Perform from Outperform at RBC Capital... athenahealth (ATHN) downgraded to Underperform from Sector Perform at RBC Capital... Boston Properties (BXP) downgraded to Neutral from Outperform at RW Baird... Cliffs Natural (CLF) downgraded to Hold from Buy at Deutsche Bank... Cubist (CBST) downgraded to Neutral from Outperform at Credit Suisse... Denbury Resources (DNR) downgraded to Equal Weight from Overweight at Barclays... E-House (EJ) downgraded to Perform from Outperform at Oppenheimer... Owens-Illinois (OI) downgraded to Market Perform from Outperform at BMO Capital... Quality Systems (QSII) downgraded to Sector Perform from Outperform at RBC Capital... Sapient (SAPE) downgraded to Hold from Buy at Stifel... Harsco (HSC) downgraded to Hold from Buy at Argus... Credit Acceptance (CACC) downgraded to Underperform from Market Perform at JMP Securities... Liberty Media (LMCA) downgraded to Hold from Buy at Telsey Advisory.
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:43 EDTCBSTCubist downgraded at Credit Suisse
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTCBSTCubist downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
15:00 EDTAMRNStonepine Capital reports 5.2% passive stake in Amarin
09:01 EDTVRNTBig data for security could reach $4B-$5B, says FBR Capital
Subscribe for More Information
08:39 EDTVRNTVerint Systems forms strategic partnership with Unify
Subscribe for More Information
November 17, 2014
09:06 EDTAMRNAmarin reports new data from MARINE, ANCHOR phase 3 studies
Amarin announced the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa capsules significantly reduced remnant-like particle cholesterol, or RLP-C, levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride, or TG, levels greater than or equal to 200 mg/dL and greater than or equal to 500 mg/dL, including patients that received statin therapy. The data were presented today by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago. Remnant-like particle cholesterol is an important emerging risk factor for cardiovascular disease and represents the cholesterol content of a subset of triglyceride-rich lipoproteins, or TRL, called remnants. In the fasting state this subset of TRLs is comprised of very low-density lipoproteins, or VLDL, and intermediate-density lipoproteins, or IDL, and in the non-fasting state includes these two types of lipoproteins together with chylomicron remnants.Elevated plasma TG levels are a marker of elevated remnant cholesterol and are associated with increased risk for cardiovascular disease.
08:02 EDTDRTXActavis completes Durata Therapeutics tender offer
Subscribe for More Information
07:16 EDTCBSTMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
05:16 EDTCBSTCubist to invest about $400M in antibiotics R&D in 2014
Subscribe for More Information
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information
November 13, 2014
10:01 EDTVRNTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ATK (ATK) downgraded to Hold from Buy at Argus... Adeptus Health (ADPT) downgraded to Hold from Buy at Deutsche Bank... American Woodmark (AMWD) downgraded to Neutral from Buy at Longbow... Avnet (AVT) downgraded to Sell from Neutral at Goldman... Baxano Surgical (BAXS) downgraded to Sell from Buy at Summer Street... Beazer Homes (BZH) downgraded to Neutral from Overweight at JPMorgan... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Morgan Stanley... Centene (CNC) downgraded to Market Perform from Outperform at FBR Capital... Cherry Hill Mortgage (CHMI) downgraded to Equal Weight from Overweight at Barclays... Discover (DFS) downgraded to Hold from Buy at Deutsche Bank... Fleetmatics (FLTX) downgraded to Neutral from Buy at BofA/Merrill... Gazprom (OGZPY) downgraded to Neutral from Overweight at JPMorgan... Jabil Circuit (JBL) downgraded to Neutral from Buy at Goldman... LabCorp (LH) downgraded to Hold from Buy at Deutsche Bank... Laredo Petroleum (LPI) downgraded at BMO Capital... Macy's (M) downgraded to Market Perform from Outperform at Wells Fargo... Madison Square Garden (MSG) downgraded to Equal Weight from Overweight at Morgan Stanley... Marvell (MRVL) downgraded to Sell from Neutral at Goldman... Meritor (MTOR) downgraded to Neutral from Overweight at Piper Jaffray... Swedbank (SWDBY) downgraded to Underperform from Sector Perform at RBC Capital... TransGlobe (TGA) downgraded to Sector Perform from Outperform at Scotia Capital... UIL Holdings (UIL) downgraded to Hold from Buy at Argus... Verint Systems (VRNT) downgraded to Fair Value from Buy at CRT Capital... ZAIS Financial (ZFC) downgraded to Equal Weight from Overweight at Barclays.
08:28 EDTVRNTVerint Systems downgraded to Fair Value at CRT Capital
Subscribe for More Information
06:46 EDTVRNTVerint Systems downgraded to Fair Value from Buy at CRT Capital
Subscribe for More Information
November 11, 2014
07:33 EDTMDRMcDermott awarded three-year shallow water pipeline contract by Brunei Shell
McDermott International has been awarded a three-year shallow water pipeline contract by Brunei Shell Petroleum Company Sdn. Bhd. to transport and install pipelines and umbilicals for the Champion and Ampa Fields offshore Brunei. Work is expected to be executed through 2017. The full scope of work will be executed in annual work plans that are expected to be confirmed over the coming years as BSP finalizes its development plans and budgets. The work identified for 2015 will be included in McDermott’s fourth quarter 2014 backlog. The first scope of work consists of transportation and installation of more than 62 miles of pipelines including corrosion resistant alloy clad pipelines, as well as umbilicals and cables. The McDermott Derrick Barge 30 and other vessels will be mobilized to support this initial work which will include hydro testing, pre-commissioning and salvage of redundant risers.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use